gemtuzumab ozogamicin

Home
Ligands
gemtuzumab ozogamicin

GtoPdb Ligand ID: 6775

Synonyms: CDP 771 | CMA 676 | hP67.6-calicheamicin | Mylotarg® | WAY-CMA 676

gemtuzumab ozogamicin is an approved drug (FDA (2000), EMA (2018))

Comment: This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells [1].

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]
2. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al.. (2012) Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood, 119 (16): 3705-11. [PMID:22378848]

References

1. Bernstein ID. (2000)
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Leukemia, 14 (3): 474-5. [PMID:10720144]

2. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al.. (2012)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Blood, 119 (16): 3705-11. [PMID:22378848]